• Treatment of severe diarrhea-predominant irritable bowel syndrome (IBS) in women who have chronic symptoms (6 mo), no other GI pathology, and have had no response to conventional therapy.

Contraindicated in:

• Hypersensitivity
• Constipation
• History of chronic/severe constipation or complications due to constipation
• History of GI obstruction, stricture, toxic megacolon, perforation, and/or adhesions
• History of ischemic colitis, ↓ intestinal circulation, thrombophlebitis, or coagulation defects
• History of Crohn’s disease/ulcerative colitis/diverticulitis
• Severe hepatic impairment
• Concurrent use of fluvoxamine

Use Cautiously in:

• Men – safety not established
• Mild-moderate hepatic impairment
• Patients who are elderly, debilitated, or taking medications that ↓ GI motility
• OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk
• Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant
• Pedi: Safety and effectiveness not established in children.

GI: constipation, abdominal discomfort, abdominal distention, ACUTE ISCHEMIC COLITIS , flatulence, nausea, GI viral infections, hemorrhoids, regurgitation or reflux, TOXIC MEGACOLON.

Drug-Drug:

• Fluvoxamine can ↑ levels; concurrent use contraindicated.
• Amiodarone, cimetidine, ciprofloxacin, clarithromycin, itraconazole, ketoconazole, ofloxacin, protease inhibitors, and voriconazole may ↑ levels; use concomitantly with caution.

(Generic available)

• Tablets: 0.5 mg; 1 mg;

• PO (Adults): Women — 0.5 mg twice daily.

Lotronex

• 5-HT₃ receptors are non-selective cation channels responsible for regulation of visceral pain, colonic transit, and GI secretions. Alosetron inhibits the activation of these channels.

• Increased colonic transit time without affecting orocecal transit time resulting in decreased pain/discomfort and diarrhea associated with IBS.

Therapeutic Classification: anti irritable bowel syndrome agents

Pharmacologic Classification: five ht3 antagonists

Absorption: 50–60% absorbed following oral administration.

Distribution: 65–95 L.

Protein Binding: 82% bound to plasma proteins.

Metabolism/Excretion: Extensively metabolized by the liver; 13% excreted unchanged in urine.

Half-life: 1.5 hr.

(pain/discomfort, diarrhea)

†Following discontinuation.

• Instruct patient to take alosetron exactly as directed. If a dose is missed, skip the dose and return to regular schedule; do not double doses. Counsel patients about the risks and benefits of alosetron and the impact of IBS symptoms on their life. Patients should read the Medication Guide before starting alosetron and each time they refill their prescription.
• Health care professionals are expected to counsel patients on the risks associated with alosetron and provide the Lotronex REMS Program Patient Education Sheet.
• Caution patient to stop taking alosetron and report constipation or signs of ischemic colitis to health care professional immediately. Immediately contact health care professional again if constipation does not resolve after discontinuation of alosetron. Alosetron should be resumed only after constipation has resolved and on the advice of their health care professional. Treatment with alosetron should not be resumed in patients who develop ischemic colitis.
• Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
• Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

a-LOW-se-tron

NDC Code^*

• 0054- West-Ward Pharmaceuticals Corp.
  • 0054-0295- Alosetron Hydrochloride
    • 0054-0295-13- 30 TABLET in 1 BOTTLE (0054-0295-13)

• 0054- West-Ward Pharmaceuticals Corp.
  • 0054-0296- Alosetron Hydrochloride
    • 0054-0296-13- 30 TABLET in 1 BOTTLE (0054-0296-13)

• 0054- West-Ward Pharmaceuticals Corp.
  • 0054-0296- Alosetron Hydrochloride
    • 0054-0296-25- 100 TABLET in 1 BOTTLE (0054-0296-25)

• 45963- Actavis Pharma, Inc.
  • 45963-479- Alosetron Hydrochloride
    • 45963-479-03- 1 BOTTLE in 1 CARTON (45963-479-03) > 30 TABLET in 1 BOTTLE

• 45963- Actavis Pharma, Inc.
  • 45963-480- Alosetron Hydrochloride
    • 45963-480-03- 1 BOTTLE in 1 CARTON (45963-480-03) > 30 TABLET in 1 BOTTLE

• 49884- Par Pharmaceutical, Inc.
  • 49884-819- ALOSETRON HYDROCHLORIDE
    • 49884-819-11- 30 TABLET in 1 BOTTLE (49884-819-11)

• 49884- Par Pharmaceutical, Inc.
  • 49884-820- ALOSETRON HYDROCHLORIDE
    • 49884-820-11- 30 TABLET in 1 BOTTLE (49884-820-11)

• 54766- Sebela Pharmaceuticals Inc.
  • 54766-894- LOTRONEX
    • 54766-894-03- 30 TABLET in 1 BOTTLE (54766-894-03)

• 54766- Sebela Pharmaceuticals Inc.
  • 54766-895- LOTRONEX
    • 54766-895-03- 30 TABLET in 1 BOTTLE (54766-895-03)

• 65162- Amneal Pharmaceuticals LLC
  • 65162-248- Alosetron Hydrochloride
    • 65162-248-03- 30 TABLET, FILM COATED in 1 BOTTLE (65162-248-03)

• 65162- Amneal Pharmaceuticals LLC
  • 65162-248- Alosetron Hydrochloride
    • 65162-248-50- 500 TABLET, FILM COATED in 1 BOTTLE (65162-248-50)

• 65162- Amneal Pharmaceuticals LLC
  • 65162-249- Alosetron Hydrochloride
    • 65162-249-03- 30 TABLET, FILM COATED in 1 BOTTLE (65162-249-03)

• 65162- Amneal Pharmaceuticals LLC
  • 65162-249- Alosetron Hydrochloride
    • 65162-249-50- 500 TABLET, FILM COATED in 1 BOTTLE (65162-249-50)